在复发性质母细胞瘤中使用贝瓦西祖马布:剂量是否重要? 我们的单心和比较经验
Giulia Cerretti1, Alberto Bosio2,3, Giovanni Librizzi4,5
1Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Gattamelata n°64, 35128, Padua, Italy. giuliacerretti@gmail.com.
Journal of neuro-oncology
|March 10, 2025
概括
贝瓦西祖马布 (阿瓦斯) 剂量为5毫克/千克或10毫克/千克,在复发性质母细胞瘤中显示出相似的生存率和毒性. 较低剂量可能提供可比的益处,并降低医疗保健成本.
科学领域:
- 神经瘤学神经瘤学
- 医学瘤学 医学瘤学
- 临床药理学 临床药理学
背景情况:
- 复发性质母细胞瘤带来了治疗挑战.
- 贝瓦西祖马布是一种抗血管性疗法,最佳剂量有争议.
- 有限的数据存在于剂量特定的结果和毒性.
研究的目的:
- 为了比较两剂bevacizumab (5 mg/kg vs. 10 mg/kg) 在质母细胞瘤复发中的疗效和安全性.
- 为了评估生存,无进展生存 (PFS) 和不同贝瓦齐祖马布治疗方案中的毒性.
- 评估贝瓦西祖马布剂量对类固醇使用和医疗保健成本的影响.
主要方法:
- 复发性IDH野生型质母细胞瘤的81名患者的回顾性分析.
- 患者每两周接受5毫克/千克或10毫克/千克的贝瓦西祖马布 (q2w).
- 贝瓦西祖马布作为单一疗法或与化疗一起使用.
主要成果:
- 在5毫克/公斤和10毫克/公斤贝瓦西祖马布组之间,PFS (两剂均为4个月) 或OS (5与7个月) 的中位数没有统计学上显著的差异.
- 两个剂量组之间的不良事件发生率和类固醇治疗使用是可比的.
- 没有观察到响应率或类固醇减少的显著差异.
结论:
- 贝瓦齐祖马布在5毫克/千克和10毫克/千克的剂量显示在复发性质母细胞瘤中具有类似的疗效和毒性.
- 可以考虑使用较低的贝瓦西祖马布剂量,为患者提供可比的益处.
- 使用较低的剂量可以节省大量的医疗保健成本.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...